News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,905 Results
Type
Article (42943)
Company Profile (297)
Press Release (682663)
Multimedia
Podcasts (94)
Webinars (16)
Section
Business (210629)
Career Advice (2095)
Deals (36677)
Drug Delivery (108)
Drug Development (83182)
Employer Resources (175)
FDA (16661)
Job Trends (15447)
News (356505)
Policy (34009)
Tag
Academia (2600)
Accelerated approval (12)
Adcomms (23)
Allergies (104)
Alliances (51579)
ALS (116)
Alzheimer's disease (1504)
Antibody-drug conjugate (ADC) (164)
Approvals (16668)
Artificial intelligence (335)
Autoimmune disease (31)
Automation (20)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (131)
Biotechnology (188)
Bladder cancer (96)
Brain cancer (38)
Breast cancer (386)
Cancer (3015)
Cardiovascular disease (233)
Career advice (1758)
Career pathing (31)
CAR-T (193)
CDC (35)
Cell therapy (522)
Cervical cancer (23)
Clinical research (68587)
Collaboration (1086)
Company closure (3)
Compensation (717)
Complete response letters (32)
COVID-19 (2707)
CRISPR (65)
C-suite (368)
Cystic fibrosis (118)
Data (3184)
Decentralized trials (2)
Denatured (31)
Depression (68)
Diabetes (354)
Diagnostics (6523)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (150)
Drug pricing (139)
Drug shortages (31)
Duchenne muscular dystrophy (149)
Earnings (89457)
Editorial (44)
Employer branding (21)
Employer resources (151)
Events (116796)
Executive appointments (881)
FDA (18472)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (964)
Gene editing (141)
Generative AI (25)
Gene therapy (412)
GLP-1 (842)
Government (4651)
Grass and pollen (6)
Guidances (220)
Healthcare (19025)
HIV (40)
Huntington's disease (31)
IgA nephropathy (41)
Immunology and inflammation (166)
Immuno-oncology (10)
Indications (42)
Infectious disease (2888)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (69)
Intellectual property (127)
Interviews (323)
IPO (16870)
IRA (53)
Job creations (4064)
Job search strategy (1494)
Kidney cancer (13)
Labor market (55)
Layoffs (527)
Leadership (20)
Legal (8403)
Liver cancer (80)
Longevity (12)
Lung cancer (420)
Lymphoma (219)
Machine learning (12)
Management (59)
Manufacturing (437)
MASH (98)
Medical device (13566)
Medtech (13572)
Mergers & acquisitions (20546)
Metabolic disorders (892)
Multiple sclerosis (100)
NASH (17)
Neurodegenerative disease (139)
Neuropsychiatric disorders (37)
Neuroscience (2238)
NextGen: Class of 2025 (6642)
Non-profit (4537)
Now hiring (50)
Obesity (451)
Opinion (244)
Ovarian cancer (104)
Pain (126)
Pancreatic cancer (129)
Parkinson's disease (191)
Partnered (22)
Patents (326)
Patient recruitment (181)
Peanut (53)
People (59752)
Pharmaceutical (91)
Pharmacy benefit managers (23)
Phase I (21263)
Phase II (30182)
Phase III (22610)
Pipeline (1739)
Policy (222)
Postmarket research (2655)
Preclinical (9079)
Press Release (68)
Prostate cancer (145)
Psychedelics (38)
Radiopharmaceuticals (259)
Rare diseases (496)
Real estate (6268)
Recruiting (68)
Regulatory (23641)
Reports (50)
Research institute (2376)
Resumes & cover letters (359)
Rett syndrome (9)
RNA editing (10)
RSV (52)
Schizophrenia (99)
Series A (162)
Series B (112)
Service/supplier (12)
Sickle cell disease (65)
Special edition (19)
Spinal muscular atrophy (151)
Sponsored (33)
Startups (3741)
State (2)
Stomach cancer (15)
Supply chain (79)
Tariffs (69)
The Weekly (61)
Vaccines (822)
Venture capital (56)
Weight loss (282)
Women's health (47)
Worklife (16)
Date
Last 7 days (524)
Last 30 days (1727)
Last 365 days (31273)
2025 (18225)
2024 (35773)
2023 (40631)
2022 (51799)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27632)
2012 (29731)
2011 (30488)
2010 (28497)
Location
Africa (788)
Alabama (63)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (41173)
Australia (6582)
California (7701)
Canada (2444)
China (709)
Colorado (325)
Connecticut (328)
Delaware (204)
Europe (88031)
Florida (1166)
Georgia (258)
Hawaii (2)
Idaho (60)
Illinois (669)
India (29)
Indiana (379)
Iowa (17)
Japan (245)
Kansas (110)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1060)
Massachusetts (5773)
Michigan (252)
Minnesota (469)
Mississippi (4)
Missouri (95)
Montana (28)
Nebraska (25)
Nevada (85)
New Hampshire (67)
New Jersey (2151)
New Mexico (29)
New York (2148)
North Carolina (1120)
North Dakota (8)
Northern California (3409)
Ohio (242)
Oklahoma (16)
Oregon (39)
Pennsylvania (1677)
Puerto Rico (17)
Rhode Island (37)
South America (1165)
South Carolina (35)
South Dakota (1)
Southern California (2894)
Tennessee (128)
Texas (1180)
United States (28632)
Utah (224)
Virginia (204)
Washington D.C. (72)
Washington State (656)
West Virginia (4)
Wisconsin (70)
725,905 Results for "amylin pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra
AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.
March 3, 2025
·
2 min read
·
Tristan Manalac
Obesity
Novo Ups Obesity Ante With $800M+ Deep Apple Pact for Oral, Non-Incretin Drugs
For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharma’s amylin efforts underwhelmed investors.
June 11, 2025
·
3 min read
·
Tristan Manalac
Weight loss
Amylin Commands Weight Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile.
December 4, 2024
·
3 min read
·
Tristan Manalac
Weight loss
Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo
At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.
June 16, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 23, 2025
·
6 min read
Press Releases
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
June 9, 2025
·
9 min read
Press Releases
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association’s 85th Scientific Sessions
June 24, 2025
·
6 min read
Drug Development
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
Viking Therapeutics, Inc. today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.
June 24, 2024
·
6 min read
Weight loss
Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Days
In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin injection MET-233i showed promising weight-loss after a little more than a month of treatment.
June 9, 2025
·
3 min read
·
Tristan Manalac
Press Releases
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
March 3, 2025
·
6 min read
1 of 72,591
Next
